What is Bristol-Myers Squibb's supply agreements — royalty income?

Bristol-Myers Squibb (BMY) reported supply agreements — royalty income of $300.00M in Q4 2025.

How has Bristol-Myers Squibb's supply agreements — royalty income changed year-over-year?

Bristol-Myers Squibb's supply agreements — royalty income decreased by 0.0% year-over-year, from $300.00M to $300.00M.

What is the long-term trend for Bristol-Myers Squibb's supply agreements — royalty income?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's supply agreements — royalty income has grown at a 13.4% compound annual growth rate (CAGR), from $725.00M to $1.20B.

What does supply agreements — royalty income mean?

Revenue earned from licensing intellectual property and supplying products to third-party partners.

Products & Services · Royalty Income

Supply Agreements — Royalty Income

Bristol-Myers Squibb Supply Agreements — Royalty Income remained flat by 0.0% to $300.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $300.00M to $300.00M. Over 4 years (FY 2021 to FY 2025), Supply Agreements — Royalty Income shows an upward trend with a 13.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryProfitability

SignalHigher is better

VolatilityModerate

First reportedQ1 2017

Last reportedQ4 2025Feb 11, 2026

How to read this metric

An increase suggests successful monetization of the company's drug portfolio through external partnerships, while a decrease may indicate expiring patents or reduced demand for licensed technologies.

Detailed definition

This metric represents the revenue generated from licensing intellectual property and providing supply chain support to...

Peer comparison

Similar to royalty and licensing revenue reported by other large-cap pharmaceutical firms, which often derive value from out-licensing non-core assets or collaborative development agreements.

Metric ID: bmy_segment_supply_agreements_royalty_income

Historical Data

5 years

	FY'21	FY'22	FY'23	FY'24	FY'25
Value	$725.00M	$924.00M	$960.00M	$1.20B	$1.20B
YoY Change	—	+27.4%	+3.9%	+25.0%	+0.0%

Range$725.00M – $1.20B

CAGR+13.4%

Avg YoY Growth+14.1%

Median YoY Growth+14.4%

Current Streak4+ years growth

Similar Metrics at Other Companies

BiogenBIIB View metric

InsmedINSM View metric

Neurocrine BiosciencesNBIX View metric

Roivant SciencesROIV View metric

Frequently Asked Questions

What is Bristol-Myers Squibb's supply agreements — royalty income?: Bristol-Myers Squibb (BMY) reported supply agreements — royalty income of $300.00M in Q4 2025.
How has Bristol-Myers Squibb's supply agreements — royalty income changed year-over-year?: Bristol-Myers Squibb's supply agreements — royalty income decreased by 0.0% year-over-year, from $300.00M to $300.00M.
What is the long-term trend for Bristol-Myers Squibb's supply agreements — royalty income?: Over 4 years (2021 to 2025), Bristol-Myers Squibb's supply agreements — royalty income has grown at a 13.4% compound annual growth rate (CAGR), from $725.00M to $1.20B.
What does supply agreements — royalty income mean?: Revenue earned from licensing intellectual property and supplying products to third-party partners.